Document Detail

Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit.
MedLine Citation:
PMID:  17337066     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To report the use of a combination of low-dose cyclophosphamide and interferon alfa 2a (IFNalpha2a) for the treatment of orbital juvenile capillary hemangioma. DESIGN: Retrospective case series. PARTICIPANTS: Five patients with juvenile capillary hemangiomas of the orbit. METHODS: Five patients with a median age of 9 weeks presented with a rapidly enlarging orbital mass. Two patients also had involvement of the upper eyelid obstructing the visual axis. Patients underwent biopsy to confirm the diagnosis before starting combination therapy with low-dose oral cyclophosphamide (10 mg/kg per day for 3 days repeated every 2 weeks) and subcutaneous IFNalpha2a (3 million units/m2 per day once daily) for a maximum treatment time of 4 to 6 months. Patients underwent serial ophthalmic, hematologic, and neurologic evaluations. MAIN OUTCOME MEASURE: Regression of lesions after combination therapy. RESULTS: Four of 5 patients had marked regression of the hemangioma by 40% to 60% with subsequent reduction in proptosis, corneal exposure, and obstruction of the visual axis. None of the 4 patients developed amblyopia. Side effects included mild neutropenia and uncomplicated infections. There was no neurologic toxicity after a median follow-up of 10 months. One patient failed to respond to treatment and required further treatment with intralesional steroid injections. CONCLUSIONS: Combination of low-dose cyclophosphamide with IFNalpha2a for a short period of time induced early and lasting regression of orbital juvenile capillary hemangiomas with minimal side effects. This regimen may be a suitable alternative that avoids the toxicity of long-term administration of interferon only. However, the experience reported here does not show if cyclophosphamide alone may be sufficient and allow complete avoidance of interferon and its potential serious side effects, and longer follow-up is needed to determine if cyclophosphamide causes any long-term harm.
Matthew W Wilson; Mary Ellen Hoehn; Barrett G Haik; Martha Rieman; Ulrike Reiss
Related Documents :
9891196 - Comparative responses to three different types of interferon-alpha in patients with chr...
20050936 - Is long-term virological response related to ccr5 delta32 deletion in hiv-1-infected pa...
20408946 - Comparison between clevudine and entecavir treatment for antiviral-naïve patients with...
18020616 - Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remit...
23773796 - Bevacizumab in age-related macular degeneration: a randomized controlled trial on the e...
12543746 - Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-03-06
Journal Detail:
Title:  Ophthalmology     Volume:  114     ISSN:  1549-4713     ISO Abbreviation:  Ophthalmology     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-30     Completed Date:  2007-05-10     Revised Date:  2007-12-18    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1007-11     Citation Subset:  IM    
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Antineoplastic Agents, Alkylating / administration & dosage*
Cyclophosphamide / administration & dosage*
Drug Therapy, Combination
Gestational Age
Hemangioma, Capillary / drug therapy*,  pathology
Interferon Alfa-2a / administration & dosage*
Orbital Neoplasms / drug therapy*,  pathology
Retrospective Studies
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents, Alkylating; 50-18-0/Cyclophosphamide; 76543-88-9/Interferon Alfa-2a
Comment In:
Ophthalmology. 2007 Dec;114(12):2369   [PMID:  18054658 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brac...
Next Document:  Psychosocial impairment associated with bipolar II disorder.